The Library
Simvastatin in the Acute Respiratory Distress Syndrome
Tools
Tools
Tools
McAuley, Daniel F., Laffey, John G., O'Kane, Cecilia M., Perkins, Gavin D., Mullan, Brian, Trinder, T. John, Johnston, Paul, Hopkins, Philip A., Johnston, Andrew J., McDowell, Cliona and McNally, Christine (2014) Simvastatin in the Acute Respiratory Distress Syndrome. New England Journal Of Medicine , 371 (18). pp. 1695-1703. doi:10.1056/NEJMoa1403285
|
PDF
WRAP-Simvastin-Acute-Syndrome-Perkins-2017.pdf - Accepted Version - Requires a PDF viewer. Download (1017Kb) | Preview |
Official URL: http://dx.doi.org/10.1056/NEJMoa1403285
Abstract
BACKGROUND
Studies in animals and in vitro and phase 2 studies in humans suggest that statins may be beneficial in the treatment of the acute respiratory distress syndrome (ARDS). This study tested the hypothesis that treatment with simvastatin would improve clinical outcomes in patients with ARDS.
METHODS
In this multicenter, double-blind clinical trial, we randomly assigned (in a 1:1 ratio) patients with an onset of ARDS within the previous 48 hours to receive enteral simvastatin at a dose of 80 mg or placebo once daily for a maximum of 28 days. The primary outcome was the number of ventilator-free days to day 28. Secondary outcomes included the number of days free of nonpulmonary organ failure to day 28, mortality at 28 days, and safety.
RESULTS
The study recruited 540 patients, with 259 patients assigned to simvastatin and 281 to placebo. The groups were well matched with respect to demographic and baseline physiological variables. There was no significant difference between the study groups in the mean (±SD) number of ventilator-free days (12.6±9.9 with simvastatin and 11.5±10.4 with placebo, P=0.21) or days free of nonpulmonary organ failure (19.4±11.1 and 17.8±11.7, respectively; P=0.11) or in mortality at 28 days (22.0% and 26.8%, respectively; P=0.23). There was no significant difference between the two groups in the incidence of serious adverse events related to the study drug.
CONCLUSIONS
Simvastatin therapy, although safe and associated with minimal adverse effects, did not improve clinical outcomes in patients with ARDS. (Funded by the U.K. National Institute for Health Research Efficacy and Mechanism Evaluation Programme and others; HARP-2 Current Controlled Trials number, ISRCTN88244364.)
| Item Type: | Journal Article | ||||||
|---|---|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine R Medicine > RM Therapeutics. Pharmacology |
||||||
| Divisions: | Faculty of Medicine > Warwick Medical School > Health Sciences > Clinical Trials Unit Faculty of Medicine > Warwick Medical School |
||||||
| Library of Congress Subject Headings (LCSH): | Respiratory distress syndrome, Adult, Statins (Cardiovascular agents) | ||||||
| Journal or Publication Title: | New England Journal Of Medicine | ||||||
| Publisher: | Massachusetts Medical Society | ||||||
| ISSN: | 0028-4793 | ||||||
| Official Date: | 30 October 2014 | ||||||
| Dates: |
|
||||||
| Date of first compliant deposit: | 20 April 2017 | ||||||
| Volume: | 371 | ||||||
| Number: | 18 | ||||||
| Page Range: | pp. 1695-1703 | ||||||
| DOI: | 10.1056/NEJMoa1403285 | ||||||
| Status: | Peer Reviewed | ||||||
| Publication Status: | Published | ||||||
| Funder: | Medical Research Council (Great Britain) (MRC), National Institute for Health Research (Great Britain) (NIHR), Scotland. Chief Scientist Office (CSO), National Institute for Social Care and Health Research (Wales) (NISCHR), Northern Ireland. Public Health Agency. HSC Research & Development Division | ||||||
| Grant number: | HRA_POR-2010-131(Northern Ireland. Public Health Agency) | ||||||
| Related URLs: |
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
Downloads
Downloads per month over past year
